Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy

Cyclin dependent kinase 4/6 inhibitors (CDK4/6i) lead to cell-cycle arrest but also trigger T cell-mediated immunity, which might be mediated by changes in human leukocyte antigen (HLA) ligands. We investigated the effects of CDK4/6i, abemaciclib and palbociclib, on the immunopeptidome at nontoxic l...

Descripción completa

Detalles Bibliográficos
Autores principales: Charles, Angel, Bourne, Christopher M., Korontsvit, Tanya, Aretz, Zita E. H., Mun, Sung Soo, Dao, Tao, Klatt, Martin G., Scheinberg, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158036/
https://www.ncbi.nlm.nih.gov/pubmed/34104540
http://dx.doi.org/10.1080/2162402X.2021.1916243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158036/
https://www.ncbi.nlm.nih.gov/pubmed/34104540
http://dx.doi.org/10.1080/2162402X.2021.1916243

Ejemplares similares